GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Valuation Rank

Immunovia AB (LTS:0G8X) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Immunovia AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Immunovia AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunovia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (LTS:0G8X) » Definitions » Valuation Rank
Comparable Companies
XSAT:GEAN OSTO:PROGEN NGM:LEVBIO OSTO:AROC NGM:LUMITO XSAT:SPERM NGM:ATANA OSTO:SENZA TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX
Traded in Other Exchanges
IMMNOV:Sweden 1YR:Germany
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Website
https://www.immunovia.com
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.